Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer.

@article{Milagre2015AdaptiveUO,
  title={Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer.},
  author={Carla S. Milagre and Ganga Gopinathan and Gemma L A Everitt and R. G. Thompson and Hagen Kulbe and Haihong Zhong and Robert E. Hollingsworth and R P Grose and David D. L. Bowtell and Daniel Hochhauser and Frances R. Balkwill},
  journal={Cancer research},
  year={2015},
  volume={75 7},
  pages={1255-64}
}
Excess production of the proinflammatory IL6 has both local and systemic tumor-promoting activity in many cancers, including ovarian cancer. However, treatment of advanced ovarian cancer patients with a neutralizing IL6 antibody yielded little efficacy in a previous phase II clinical trial. Here, we report results that may explain this outcome, based on the… CONTINUE READING